Baker Botts attorneys Paul Lugard, Jody Boudreault and Jonathan Huie explain how some recent decisions by the European Union's executive arm could affect the patent rights that pharmaceutical companies hold.

For a complete copy of this article please click the title link below.

EC's Teva and Vifor decisions threaten patent and marketing strategies in the life sciences sector and beyond — Will FTC follow?